Aptamer Group (LSE:APTA) has secured a substantial £360,000 agreement with one of the world’s top three pharmaceutical companies to develop Optimer® binders for targeted radiopharmaceutical applications, including potential therapeutic uses. This deal marks an important step into the rapidly growing US$7.5 billion targeted radiopharmaceuticals market and could open the door to future licensing and royalty opportunities.
In addition to this flagship contract, Aptamer has signed a further £665,000 in new agreements and project extensions. These include collaborations with a top five global pharmaceutical company and a therapeutic partnership with Invizius. Together, these projects have helped build a strong sales pipeline valued at £3.4 million, providing a solid foundation for revenue growth in the current fiscal year.
Despite these commercial wins, Aptamer Group Plc continues to face financial headwinds. Persistent losses, debt reliance, and weak technical indicators weigh on its short-term outlook. However, the company’s expanding portfolio of partnerships and growing presence in high-value life sciences markets offer encouraging signs for long-term growth potential.
About Aptamer Group Plc
Aptamer Group is a biotechnology company developing next-generation synthetic binders—known as Optimer® binders—for use across the life sciences sector. Designed as advanced alternatives to antibodies, Optimer® binders offer enhanced stability, lower production costs, and broad applications in therapeutics, diagnostics, and research. Operating primarily through a fee-for-service model, the company collaborates with leading pharmaceutical partners to develop custom Optimer® assets, building a foundation for future licensing revenues. Founded in 2008 and headquartered in York, UK, Aptamer Group is listed on the AIM market of the London Stock Exchange.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply